Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Euro-Med Laboratories Philippines 3-Year ROIIC %?
Euro-Med Laboratories PhilippinesPHS:EURO 82 3-Year ROIIC % is 91.00 as of Dec. 2025, which is 1125% above its 10-year median of 7.43. GuruFocus rates PHS:EURO with a GF Score™ of 82/100 and a GF Value™ of ₱1.03 (Fairly Valued). The stock has 7 warning signs investors should review. Among 948 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 89.03% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Euro-Med Laboratories Philippines's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 91.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Euro-Med Laboratories Philippines 3-Year ROIIC % Related Terms
Euro-Med Laboratories Philippines 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Euro-Med Laboratories Philippines (PHS:EURO) has a 3-Year ROIIC % of 91.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 1125% above median its historical median of 7.43. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #104 out of 948 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Euro-Med Laboratories Philippines' 3-Year ROIIC % too high?
Euro-Med Laboratories Philippines' current 3-Year ROIIC % of 91.00 is 1125% above median its 10-year median of 7.43. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Euro-Med Laboratories Philippines' value of 91.00 is 2346.2% above this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #104 out of 948 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #104 out of 948 companies for 3-Year ROIIC %. This places Euro-Med Laboratories Philippines in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Euro-Med Laboratories Philippines' value of 91.00 is 2346.2% above this benchmark. While the company's 10-year median is 7.43 vs. the industry median of 3.72, Euro-Med Laboratories Philippines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current 3-Year ROIIC % of 91.00 is 2346.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current 3-Year ROIIC % is 91.00, which is 1125% above median its own 10-year median of 7.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.03, compared to a current price of ₱1.10 — trading 6.8% above its estimated fair value. The current 3-Year ROIIC % is 91.00, which is 1125% above median its 10-year median of 7.43 and 2346.2% above the Drug Manufacturers industry median of 3.72. Euro-Med Laboratories Philippines' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current 3-Year ROIIC % is 91.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.10 is trading 6.8% above its estimated GF Value™ of ₱1.03.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
3-Year ROIIC %: 91.00 (1125% above median its 10-year median of 7.43)
GF Value™: ₱1.03 vs. price of ₱1.10 (6.8% above fair value)
Industry Position: 2346.2% above the Drug Manufacturers median (#104 of 948)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
82GF Score
Get the complete analysis for PHS:EURO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
